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 Cardiovascular disease has been estab-
lished as the leading cause of death in 
adults with childhood-onset end-stage 
renal disease (ESRD). Initial data demon-
strating this phenomenon came from 
analysis of data from the United States 
Renal Data System, which collects infor-
mation on essentially all US ESRD patients. 
In this study, 1 among 1380 patients with 
childhood-onset ESRD who died before 
30 years of age, 23 % of deaths were cardio-
vascular in origin; the cardiovascular death 
rate was 1000 times higher among children 
with ESRD than in the general population, 
and 100 times higher among young adults 
with ESRD than in the general population. 
Further data have been provided by the 
Late Eff ects of Renal Insuffi  ciency in Chil-
dren (LERIC) study, a cohort study of 249 
Dutch adult patients with onset of ESRD 
between 0 and 14 years of age. 2 Th e overall 
mortality risk of the ESRD patients was 31 
times that of age-matched Dutch citizens, 
and cardiovascular disease accounted for 
41 % of all mortalities, with cardiac death 
becoming the most common cause of 
mortality aft er 10 years of receiving renal 
replacement therapy. 2 
 Although neither of these observa-
tional studies can provide explanations 
for the astonishingly high rates of car-
diovascular disease in children and 
young adults with ESRD, it is also well 
established that chronic kidney disease 
(CKD) is associated with numerous tra-
ditional and nontraditional cardiovascu-
lar risk factors, even in pediatric patients 
( Table 1 ). It is thought that the combina-
tion of these many risk factors, especially 
over many years of CKD and renal 
replacement therapy, leads to an accel-
eration in various pathophysiologic 
processes, chief among them atheroscle-
rosis and myocardial hypertrophy. Th is 
has been reviewed in detail elsewhere. 3 
Th e task for the clinician is to identify 
which cardiovascular risk factors are 
present in an individual patient, and 
institute appropriate changes in manage-
ment to reduce the patient ’ s overall 
cardiovascular risk. 
 Hypertension is perhaps one of the most 
common of the traditional cardiovascular 
risk factors seen in young CKD and ESRD 
patients and is a risk factor that should be 
modifi able. Until recently, however, reliable 
data on the prevalence of hypertension in 
children with CKD or ESRD were limited. 
For pediatric CKD, for example, most 
available information on blood pressure 
(BP) came from registry reports such as 
those from the North American Pediatric 
Renal Trials and Collaborative Studies, 
which did demonstrate substantial rates of 
hypertension, whether hyper tension was 
defi ned as treatment with antihypertensive 
medications, or as elevated measured BP. 4 
More complete data have been provided by 
the prospective observational Chronic 
Kidney Disease in Children (CKiD) cohort 
study, 5 which has demonstrated that 
approximately 54 % of children with CKD 
demonstrate hypertension (defined as 
measured BP   95 th percentile and / or his-
tory of hypertension with antihypertensive 
medication use), with many more children 
demonstrating measured BP   >  90 th per-
centile, the current recommended goal BP 
for children with CKD. 4 
 Data on BP levels in pediatric ESRD 
patients have also come primarily from 
registry reports. Mitsnefes  et al. 6 reported 
that about 60 % of pediatric dialysis 
patients had uncontrolled hypertension, 
defi ned as measured BP   95 th percentile. 
Young age, recent dialysis initiation, and 
hemodialysis (HD) modality were identi-
fi ed as risk factors for having uncontrolled 
BP. Similar poor control of hypertension 
in US dialysis patients has been reported 
by Chavers  et al. 7 for HD patients and 
Halbach  et al. 8 for both HD and perito-
neal dialysis (PD) patients. In the latter 
study, demographic factors such as black 
ethnicity and treatment factors such as 
prescription of antihypertensive medica-
tions were also identifi ed as risk factors 
for poorly controlled hypertension. Both 
of these studies are notable for their reli-
ance on registry data; thus, there is limited 
information available on the technique 
and / or frequency of BP measurement, or 
the goals of hypertension management. 
 Fewer data are available on pediatric 
transplant recipients; most reports to date 
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come from single-center studies such as 
that of Sinha  et al. , 9 who reported a preva-
lence of hypertension of more than 50 % 
among pediatric renal transplant recipi-
ents followed at Great Ormond Street 
Hospital. In that study, uncontrolled hyper-
tension was more likely, and the number 
of antihypertensive medications was 
greater, among children with more severe 
CKD. Although this study is notable for 
the consistency of BP measurement, the 
study population is small, limiting the 
conclusions that can be drawn regarding 
factors aff ecting BP control. 
 Kramer  et al. 10 (this issue) now report 
data from the European Society for Paedi-
atric Nephrology / European Renal Asso-
ciation – European Dialysis and Transplant 
Association (ESPN / ERA-EDTA) Registry 
on BP control among pediatric ESRD 
patients in Europe, including patients 
receiving HD or PD as well as renal trans-
plant patients. Th ey confi rm the poor con-
trol of hypertension reported in the earlier 
studies noted above; specifi cally, hyper-
tension was present in 69.4 % of HD, 68.6 % 
of PD, and 66.9 % of transplant recipients. 
Among dialysis patients, their data confi rm 
earlier reports that younger age, recent 
dialysis initiation, and HD modality are 
risk factors for poor BP control among the 
dialysis group; the best control of BP was 
seen among transplant recipients, although 
no correlation between CKD stage and BP 
control was made as in the report from 
Great Ormond Street. 9 A signifi cant fl aw 
in the report from Kramer  et al. 10 is that no 
information is provided as to the method 
of BP measurement, a problem that can 
hopefully be rectifi ed in the centers par-
ticipating in this registry going forward. 
Th e CKiD Study report 5 demonstrates that 
a common BP measurement protocol can 
be followed across many centers, and that 
such an approach produces more reliable 
data compared with BP measurements 
obtained by a variety of techniques. 
 Sustained control of hypertension over 
time is perhaps the most important factor 
in reducing future cardiovascular risk, but 
few data are available on whether this can 
be achieved in pediatric CKD and ESRD 
patients. Th e report of Kramer  et al. 10 pro-
vides limited information on this topic. 
Th ey demonstrate that normotensive HD 
patients or transplant recipients tended to 
show increases in BP over time, whereas 
PD patients tended to show stable BP. 10 
Th e longitudinal data in this study are 
compromised by the relatively small 
number ( n  =  325) of patients with available 
longitudinal BP data. More promising 
results can be found in the study of 
Halbach  et al. , 8 who demonstrated a trend 
toward improved BP control in a large 
cohort of US dialysis patients. Ideally, a 
cohort of patients such as that enrolled in 
the CKiD study 5 should be followed over 
the course of their CKD, and progression 
through dialysis and transplantation, with 
follow-up extended into adulthood. To 
date, no such study has been conducted. 
 Where do we go from here — how should 
the problem of poor BP control among pedi-
atric CKD and ESRD patients be addressed 
so that future cardiovascular morbidity and 
mortality can be reduced? Th e available lit-
erature suggests several approaches: First, 
BP in this population needs to be carefully 
and consistently measured so that reliable 
BP data will be available to guide treatment. 
Ambulatory BP monitoring, not included 
in the studies cited here, may also play an 
important role in BP assessment in this 
population. Second, greater eff orts should 
be made to control BP among young CKD 
and ESRD patients, particularly within the 
fi rst year of their starting renal replacement 
therapy. Early control of hypertension may 
be particularly important in reducing future 
cardiovascular risk. Finally, we need better 
understanding of what medications to use 
and how to use them — this applies not only 
to antihypertensive medications, but also to 
medications used to control secondary 
hyperparathyroidism, dyslipidemia, insulin 
resistance, and the multitude of other 
lifelong complications of early-onset CKD. 
Only a comprehensive approach that 
addresses BP in the context of overall 
cardiovascular risk will be successful in 
reversing the cardiovascular morbidity of 
childhood-onset CKD and ESRD. 
 DISCLOSURE 
 The author declared no competing interests. 
 REFERENCES 
 1 .  Parekh  RS ,  Carroll  CE ,  Wolfe  RA  et al.  Cardiovascular 
mortality in children and young adults with 
end-stage kidney disease .  J Pediatr  2002 ;  141 : 
 191 – 197 . 
 2 .  Groothoff  J ,  Gruppen  M ,  de Groot  E  et al. 
 Cardiovascular disease as a late complication of 
end-stage renal disease in children .  Perit Dial Int 
 2005 ;  25 (Suppl 3) :  S123 – S126 . 
 3 .  Lillen  MR ,  Groothoff  JW .  Cardiovascular disease in 
children with CKD or ESRD .  Nat Rev Nephrol  2009 ; 
 5 :  229 – 235 . 
 4 .  Shatat  IF ,  Flynn  JT .  Hypertension in children with 
chronic kidney disease .  Adv Chronic Kidney Dis 
 2005 ;  12 :  378 – 384 . 
 5 .  Flynn  JT ,  Mitsnefes  M ,  Pierce  C  et al.  Blood pressure 
in children with chronic kidney disease: a report 
from the Chronic Kidney Disease in Children study . 
 Hypertension  2008 ;  52 :  631 – 637 . 
 6 .  Mitsnefes  M ,  Stablein  D .  Hypertension in pediatric 
patients on long-term dialysis: a report of the 
North American Pediatric Renal Transplant 
Cooperative Study (NAPRTCS) .  Am J Kidney Dis 
 2005 ;  45 :  309 – 315 . 
 7 .  Chavers  BM ,  Solid  CA ,  Daniels  FX  et al. 
 Hypertension in pediatric long-term hemodialysis 
patients in the United States .  Clin J Am Soc Nephrol 
 2009 ;  4 :  1363 – 1369 . 
 8 .  Halbach  S ,  Martz  K ,  Matoo  T  et al.  Control of 
hypertension in pediatric dialysis patients .  J Am 
Soc Nephrol  2009 ;  20 (Abstracts Issue) :  40A  [abstr] . 
 9 .  Sinha  R ,  Saad  A ,  Marks  SD .  Prevalence and 
complications of chronic kidney disease in 
paediatric renal transplantation: a K/DOQI 
perspective .  Nephrol Dial Transplant  2010 ;  25 : 
 1313 – 1320 . 
 10 .  Kramer  AM ,  van Stralen  KJ ,  Jager  KJ  et al.  
 Demographics of blood pressure and 
hypertension in children on renal replacement 
therapy in Europe .  Kidney Int  2011 ;  80 :  1092 – 1098 . 
 Table 1  |  Traditional and nontraditional 
cardiovascular risk factors in patients 
with CKD 
 Traditional  Nontraditional 
 Age  Renal insuffi  ciency 
 Ethnicity  Microalbuminuria /
 proteinuria 
 Gender  Hyperparathyroidism 
 Hypertension  Anemia 
 Dyslipidemia  Impaired glucose 
metabolism 
 Diabetes mellitus  Chronic infl ammation 
 Tobacco use  Hyperhomo-
cysteinemia 
 Sedentary lifestyle  Thrombotic 
alterations 
 Psychosocial 
stress 
 Endothelial 
dysfunction 
 Family history  Fluid overload 
 Left ventricular 
hypertrophy 
 Decreased 
adiponectin 
 Obesity  Vascular calcifi cation 
